The agreement to gain rights outside of China to a portfolio of early-stage experimental obesity and diabetes drugs could be ...
Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the ...
Researchers reviewed the body mass index of over 11 million Americans.
Using data culled from nearly 11 million people, the researchers found that just over 19% were obese in 1990, compared to ...
AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...
The prevalence of obese adults in the United States more than doubled between 1990 and 2022.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...
BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...
Researchers projected that adult obesity rates in the U.S. will rise to 47% in the next decade. Multifactorial strategies ...
The deal, which involves up to 8 “next-generation” weight loss medications and could be worth more than $18 billion, ranks as ...
7don MSN
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...
Is Obesity Genetic or Environmental? Get All the Details This article was reviewed by Lynn Marie Morski, MD, JD. Key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results